This content is machine translated Thyroid Cancer System therapy: Current developments Targeted systemic therapies have become increasingly important in both anaplastic and advanced radioiodine-refractory differentiated thyroid carcinoma. These have proven to be effective options over the past several years in the…
View Post 12 min This content is machine translated Medullary thyroid carcinoma Calcitonin as a tumor marker Thyroid nodules are a well-known phenomenon; fortunately, medullary thyroid carcinomas are not. It is a malignant degeneration of the C cells of the thyroid gland, which are located parafollicularly and…
View Post 12 min This content is machine translated Medullary thyroid carcinoma Calcitonin as a tumor marker Thyroid nodules are a well-known phenomenon; fortunately, medullary thyroid carcinomas are not. It is a malignant degeneration of the C cells of the thyroid gland, which are located parafollicularly and…
View Post 9 min This content is machine translated Thyroid carcinomas State of the Art Therapy Thyroid carcinomas can be diagnosed well today thanks to modern imaging techniques and often have a good prognosis. However, postoperative risk stratification should take place at a center with a…
View Post 6 min This content is machine translated Current status of a nearly 70-year therapy Radioiodine therapy in differentiated thyroid carcinoma. For papillary and follicular thyroid carcinomas, ablative radioiodine therapy with TSH stimulation is given four to six weeks after surgery. Studies show that high standard activity (3.7 GBq vs. 1.1…
